Patents by Inventor Tanja Weil
Tanja Weil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220025544Abstract: A method for low-pressure diamond growth includes heating a composition comprising a diamond growth seed and a source of reactive carbon to a temperature below 800° C., wherein the heating takes place under low pressure. Responsive to the heating, growing diamonds from the composition.Type: ApplicationFiled: November 1, 2019Publication date: January 27, 2022Inventors: Philip R. Hemmer, Masfer Hassan A. Alkahtani, Fedor Jelezko, Todd Zapata, Tanja Weil, Isaac V. Rampersaud
-
Patent number: 10883096Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: GrantFiled: December 14, 2018Date of Patent: January 5, 2021Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20200024588Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: December 14, 2018Publication date: January 23, 2020Applicant: IPSEN BIOINNOVATION LIMITEDInventors: Andreas RUMMEL, Tanja WEIL, Aleksandrs GUTCAITS
-
Patent number: 10266816Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: GrantFiled: April 7, 2017Date of Patent: April 23, 2019Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20170275607Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: April 7, 2017Publication date: September 28, 2017Inventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Patent number: 9650622Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: GrantFiled: August 5, 2014Date of Patent: May 16, 2017Assignee: Ipsen Bioinnovation LimitedInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Patent number: 9115350Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: GrantFiled: April 22, 2013Date of Patent: August 25, 2015Assignee: Syntaxin LimitedInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20150038401Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Applicant: SYNTAXIN LIMITEDInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20130315888Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: April 22, 2013Publication date: November 28, 2013Applicant: SYNTAXIN LIMITEDInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Patent number: 8481040Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragma assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: GrantFiled: April 26, 2006Date of Patent: July 9, 2013Assignee: Syntaxin LimitedInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20120178742Abstract: The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: ApplicationFiled: August 3, 2010Publication date: July 12, 2012Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Markus Henrich, Tanja Weil, Mirko Hechenberger, Sibylle Muller, Valerjans Kauss, Ronalds Zemribo, Elina Erdmane, Gints Smits
-
Publication number: 20110212956Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: ApplicationFiled: May 3, 2011Publication date: September 1, 2011Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaitas, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Patent number: 7985753Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: GrantFiled: August 3, 2007Date of Patent: July 26, 2011Assignee: MERZ PHARMA GmbH & Co. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Patent number: 7947689Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.Type: GrantFiled: August 3, 2007Date of Patent: May 24, 2011Assignee: Merz Pharma GmbH & Co. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20110003820Abstract: The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: ApplicationFiled: January 30, 2009Publication date: January 6, 2011Applicant: MERZ PHARMA GMBH & CO. KGaAInventors: Markus Henrich, Tanja Weil, Sibylle Muller, Jens Nagel, Andreas Gravius, Valerjans Kauss, Ronalds Zemribo, Elina Erdmane
-
Publication number: 20090311275Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragma assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: April 26, 2006Publication date: December 17, 2009Inventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Patent number: 7598384Abstract: The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: GrantFiled: February 25, 2005Date of Patent: October 6, 2009Assignee: Merz Pharma GmbH & Co. KGAAInventors: Aigars Jirgensons, Christopher Graham Raphael Parsons, Ieva Jaunzeme, Ivars Kalvinsh, Markus Henrich, Maksims Vanejevs, Tanja Weil, Valerjans Kauss, Wojciech Danysz
-
Publication number: 20090227582Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: ApplicationFiled: May 8, 2009Publication date: September 10, 2009Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher G.R. Parsons, Tanja Weil
-
Patent number: 7550482Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: GrantFiled: August 24, 2005Date of Patent: June 23, 2009Assignee: Merz Pharma GmbH & Co. KGAAInventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher Graham Raphael Parsons, Tanja Weil
-
Publication number: 20080039458Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: ApplicationFiled: August 3, 2007Publication date: February 14, 2008Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss